These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3157960)

  • 41. Lymphocyte subsets and surface molecules in man.
    Krensky AM; Lanier LL; Engleman EG
    Clin Immunol Rev; 1985; 4(1):95-138. PubMed ID: 2992859
    [No Abstract]   [Full Text] [Related]  

  • 42. Modification of emerging repertoires by immunosuppression in immunodeficient mice results in autoimmunity.
    Marcos MA; de la Hera A; Gaspar ML; Márquez C; Bellas C; Mampaso F; Toribio ML; Martínez C
    Immunol Rev; 1986 Dec; 94():51-74. PubMed ID: 3100422
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunologic markers for classification of leukemias and non-Hodgkin lymphomas.
    Thierfelder S; Rodt H; Thiel E; Hoffmann-Fezer G; Netzel B; Haas RJ; Wündisch GF; Bender-Götze C
    Recent Results Cancer Res; 1979; 69():41-8. PubMed ID: 382307
    [No Abstract]   [Full Text] [Related]  

  • 44. Summary: symposium on Epstein-Barr virus-induced lymphoproliferative diseases in immunodeficient patients.
    Klein G; Purtilo D
    Cancer Res; 1981 Nov; 41(11 Pt 1):4302-4. PubMed ID: 6272974
    [No Abstract]   [Full Text] [Related]  

  • 45. [Immunologic cell markers in lymphoproliferative diseases].
    Samoĭlova RS
    Ter Arkh; 1980; 52(9):140-9. PubMed ID: 7001662
    [No Abstract]   [Full Text] [Related]  

  • 46. Normal and neoplastic lymphocyte maturation.
    Weissman IL; McGrath MS; Pillemer E; Hollander N; Rouse RV; Jerabek L; Stevens SK; Scollay RG; Butcher EC
    J Supramol Struct Cell Biochem; 1981; 15(3):303-14. PubMed ID: 6790720
    [No Abstract]   [Full Text] [Related]  

  • 47. Editorial: Membrane markers in lymphoproliferative disorders.
    Lancet; 1975 Mar; 1(7908):670-1. PubMed ID: 47088
    [No Abstract]   [Full Text] [Related]  

  • 48. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies.
    Nadler LM; Ritz J; Griffin JD; Todd RF; Reinherz EL; Schlossman SF
    Prog Hematol; 1981; 12():187-225. PubMed ID: 7041173
    [No Abstract]   [Full Text] [Related]  

  • 49. The T cell circuit: clinical and biological implications.
    Romain PL; Schlossman SF
    Adv Intern Med; 1986; 31():1-16. PubMed ID: 2868620
    [No Abstract]   [Full Text] [Related]  

  • 50. Control of lymphocyte function.
    Bleich HL; Boro ES
    N Engl J Med; 1976 Nov; 295(21):1180-6. PubMed ID: 185516
    [No Abstract]   [Full Text] [Related]  

  • 51. Subpopulations of human T lymphocytes: laboratory and clinical studies.
    Gupta S; Good RA
    Immunol Rev; 1981; 56():89-114. PubMed ID: 7016736
    [No Abstract]   [Full Text] [Related]  

  • 52. T cells and T-cell subsets in a large population of patients with primary immunodeficiency.
    Buckley RH; Gard S; Schiff RI; Sampson HA
    Birth Defects Orig Artic Ser; 1983; 19(3):187-91. PubMed ID: 6228268
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluation of lymphocyte differentiation in primary and secondary immunodeficiency diseases.
    Tedder TF; Crain MJ; Kubagawa H; Clement LT; Cooper MD
    J Immunol; 1985 Sep; 135(3):1786-91. PubMed ID: 3160779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies of T and B lymphocytes functions in immunodeficiency.
    Daguillard F; Griscelli C
    Biomedicine; 1979 Feb; 30(1):13-5. PubMed ID: 313816
    [No Abstract]   [Full Text] [Related]  

  • 55. [Immunoprofile of LMIF in immunologic deficiency syndromes. II. Mediator production by isolated subpopulations of human lymphocytes].
    Górski A
    Pol Arch Med Wewn; 1978 Apr; 59(4):395-401. PubMed ID: 149303
    [No Abstract]   [Full Text] [Related]  

  • 56. Humoral factors influencing lymphocyte transformation.
    Nelson DS; Gatti RA
    Prog Allergy; 1976; 21():261-341. PubMed ID: 63955
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of haematological malignancies and their treatment on host defence factors.
    Hersh EV; Gutterman JU; Mavligit GM
    Clin Haematol; 1976 Jun; 5(2):425-48. PubMed ID: 780032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Monoclonal antibodies IPO-4 recognizing antigen-activated human T and B lymphocytes].
    Sidorenko SP; Berdova AG; Vetrova EP; Shlapatskaia LN; Iurchenko OV; Evsev'eva AI; Gluzman DF
    Eksp Onkol; 1990; 12(3):21-4. PubMed ID: 2344819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lymphocytes, lymphocyte subpopulations and diseases related to abnormalities of suppressor-cell function].
    Hsieh KH
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1980 Jun; 13(2):209-28. PubMed ID: 6450035
    [No Abstract]   [Full Text] [Related]  

  • 60. [Assessment of the immunodeficiency of patients with lymphomata in relapse and in clinical remission (author's transl)].
    Ruibal Ares B; Sasiain M; Brezavscek DM; Suarez A; Bachmann AE
    Sangre (Barc); 1978; 23(5):535-43. PubMed ID: 311077
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.